Home LiteratureArticle Details
PMID: 20458021 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Circulation ·Vol. 121 ·No. 18 ·2010-05-11 ·Pages 2045-66

Archer SL, Weir EK, Wilkins MR

Abstract

暂无摘要

MeSH Terms
Animals Cardiology Heart Failure/pathology,physiopathology,therapy Humans Hypertension, Pulmonary/pathology,physiopathology,therapy
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Archer Stephen L
University of Chicago, IL 60637, USA. sarcher@medicine.bsd.uchicago.edu
Weir E Kenneth
Wilkins Martin R
References (196)
196 references, click to expand
  1. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.
    Am J Physiol Lung Cell Mol Physiol. 2007 Apr;292(4):L885-97 PMID: 17189321
  2. A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension.
    Circulation. 2009 May 5;119(17):2313-22 PMID: 19380626
  3. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.
    N Engl J Med. 1992 Jul 9;327(2):70-5 PMID: 1603138
  4. Effects of erythropoietin on advanced pulmonary vascular remodelling.
    Eur Respir J. 2008 Jan;31(1):126-34 PMID: 17898019
  5. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension.
    Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L583-90 PMID: 17586694
  6. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.
    Circulation. 2008 Aug 12;118(7):722-30 PMID: 18663089
  7. A USA-based registry for pulmonary arterial hypertension: 1982-2006.
    Eur Respir J. 2007 Dec;30(6):1103-10 PMID: 17804449
  8. Organization and regulation of mitogen-activated protein kinase signaling pathways.
    Curr Opin Cell Biol. 1999 Apr;11(2):211-8 PMID: 10209154
  9. Chronic hypoxia is associated with reduced delayed rectifier K+ current in rat pulmonary artery muscle cells.
    Am J Physiol. 1994 Jan;266(1 Pt 2):H365-70 PMID: 8304521
  10. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era.
    Am J Respir Crit Care Med. 2009 Jan 15;179(2):151-7 PMID: 18931333
  11. Alterations of cellular bioenergetics in pulmonary artery endothelial cells.
    Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1342-7 PMID: 17227868
  12. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension.
    Circ J. 2006 Feb;70(2):174-8 PMID: 16434811
  13. Chronic hypoxia decreases K(V) channel expression and function in pulmonary artery myocytes.
    Am J Physiol Lung Cell Mol Physiol. 2001 Apr;280(4):L801-12 PMID: 11238022
  14. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
    Circ Res. 2006 Feb 3;98(2):209-17 PMID: 16357305
  15. Activation of K+ channels: an essential pathway in programmed cell death.
    Am J Physiol Lung Cell Mol Physiol. 2004 Jan;286(1):L49-67 PMID: 14656699
  16. Serotonin induces Rho/ROCK-dependent activation of Smads 1/5/8 in pulmonary artery smooth muscle cells.
    FASEB J. 2009 Jul;23(7):2299-306 PMID: 19244313
  17. An epidemiological study of pulmonary arterial hypertension.
    Eur Respir J. 2007 Jul;30(1):104-9 PMID: 17360728
  18. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension.
    Pulm Pharmacol Ther. 2006;19(5):370-4 PMID: 16483811
  19. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.
    Am J Respir Crit Care Med. 2003 May 15;167(10):1433-9 PMID: 12615632
  20. Calcium and TRP channels in pulmonary vascular smooth muscle cell proliferation.
    News Physiol Sci. 2004 Apr;19:44-50 PMID: 15016901
  21. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.
    ChemMedChem. 2009 May;4(5):853-65 PMID: 19263460
  22. Pulmonary artery smooth muscle cells from normal subjects and IPAH patients show divergent cAMP-mediated effects on TRPC expression and capacitative Ca2+ entry.
    Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1202-10 PMID: 17189322
  23. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
    Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1500-6 PMID: 10556112
  24. Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer.
    Am J Respir Cell Mol Biol. 2006 Aug;35(2):182-9 PMID: 16543611
  25. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.
    N Engl J Med. 1993 Jun 17;328(24):1732-9 PMID: 8497283
  26. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension.
    J Am Coll Cardiol. 1998 Jan;31(1):202-8 PMID: 9426041
  27. Signal transduction by the TGF-beta superfamily.
    Science. 2002 May 31;296(5573):1646-7 PMID: 12040180
  28. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.
    Circulation. 2005 Jun 14;111(23):3105-11 PMID: 15939821
  29. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling.
    Am J Respir Crit Care Med. 2007 Jun 15;175(12):1280-9 PMID: 17413127
  30. Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling.
    J Pharmacol Exp Ther. 2008 May;325(2):370-9 PMID: 18252813
  31. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.
    Circ Res. 2004 Apr 30;94(8):1109-14 PMID: 15031260
  32. Chronic EDRF inhibition and hypoxia: effects on pulmonary circulation and systemic blood pressure.
    J Appl Physiol (1985). 1993 Oct;75(4):1748-57 PMID: 7506706
  33. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.
    Cancer Cell. 2007 Jan;11(1):37-51 PMID: 17222789
  34. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension.
    Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9488-93 PMID: 12878719
  35. Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus.
    Am J Physiol Lung Cell Mol Physiol. 2005 Apr;288(4):L727-33 PMID: 15608146
  36. Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation.
    Am J Physiol Heart Circ Physiol. 2001 Feb;280(2):H746-55 PMID: 11158974
  37. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans.
    Circulation. 1994 May;89(5):2035-40 PMID: 7514109
  38. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
    Circulation. 2009 Feb 3;119(4):566-76 PMID: 19153267
  39. Genetic basis of pulmonary arterial hypertension: current understanding and future directions.
    J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):33S-39S PMID: 15194176
  40. Nitric oxide synthase in pulmonary hypertension: lessons from knockout mice.
    Physiol Res. 2000;49(5):539-48 PMID: 11191358
  41. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.
    Annu Rev Biochem. 2007;76:481-511 PMID: 17376027
  42. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle.
    J Mol Med (Berl). 2010 Jan;88(1):47-60 PMID: 19949938
  43. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.
    Circulation. 2001 Aug 14;104(7):790-5 PMID: 11502704
  44. Oxidative stress in severe pulmonary hypertension.
    Am J Respir Crit Care Med. 2004 Mar 15;169(6):764-9 PMID: 14701708
  45. Reactivation of gammaHV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin.
    Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L276-89 PMID: 18083765
  46. Cyclosporin A inhibits hypoxia-induced pulmonary hypertension and right ventricle hypertrophy.
    Am J Respir Crit Care Med. 2006 Sep 15;174(6):699-705 PMID: 16799071
  47. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis.
    J Pathol. 2001 Oct;195(3):367-74 PMID: 11673836
  48. Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension.
    Respir Med. 2008 Jul;102(7):1073-9 PMID: 18394873
  49. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease.
    Circulation. 2003 Oct 14;108(15):1839-44 PMID: 14530202
  50. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene.
    Circulation. 2007 Mar 13;115(10):1260-8 PMID: 17309917
  51. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
    N Engl J Med. 1996 Feb 1;334(5):296-301 PMID: 8532025
  52. Pathologic regression of primary pulmonary hypertension in left native lung following right single-lung transplantation.
    J Heart Lung Transplant. 2001 Mar;20(3):381-4 PMID: 11257567
  53. Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats.
    Biochem Biophys Res Commun. 2006 Oct 20;349(2):781-8 PMID: 16956581
  54. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
    Br J Pharmacol. 2002 Dec;137(8):1187-94 PMID: 12466227
  55. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA.
    Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L18-24 PMID: 16891395
  56. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy.
    Am J Pathol. 2004 Jan;164(1):253-62 PMID: 14695338
  57. Mechanisms for increased glycolysis in the hypertrophied rat heart.
    Hypertension. 2004 Nov;44(5):662-7 PMID: 15466668
  58. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload.
    Circulation. 2004 Aug 10;110(6):718-23 PMID: 15289381
  59. Spotlight on sapropterin in primary hyperphenylalaninemia.
    BioDrugs. 2009;23(3):201-2 PMID: 19627172
  60. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension.
    Circulation. 2005 Jul 19;112(3):423-31 PMID: 16027270
  61. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension.
    Circ Res. 2006 May 26;98(10):1323-30 PMID: 16614302
  62. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.
    Circulation. 2007 Jul 17;116(3):238-48 PMID: 17606845
  63. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.
    Circulation. 2002 May 21;105(20):2398-403 PMID: 12021227
  64. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep.
    Am J Physiol Lung Cell Mol Physiol. 2005 Nov;289(5):L798-806 PMID: 15964898
  65. Inhibition of hypoxic pulmonary hypertension by heparins of differing in vitro antiproliferative potency.
    Am J Respir Crit Care Med. 1994 Jun;149(6):1512-7 PMID: 8004307
  66. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease.
    Circulation. 2009 Jan 27;119(3):374-81 PMID: 19139384
  67. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.
    N Engl J Med. 1995 Jul 27;333(4):214-21 PMID: 7540722
  68. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.
    Eur Respir J. 2004 Sep;24(3):371-4 PMID: 15358693
  69. In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats.
    Circulation. 2003 Apr 22;107(15):2037-44 PMID: 12695303
  70. Pulmonary arterial hypertension in France: results from a national registry.
    Am J Respir Crit Care Med. 2006 May 1;173(9):1023-30 PMID: 16456139
  71. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation.
    Circulation. 2007 Mar 13;115(10):1275-84 PMID: 17339547
  72. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
    Physiol Genomics. 2008 Apr 22;33(2):278-91 PMID: 18303084
  73. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension?
    J Lab Clin Med. 2002 Apr;139(4):194-201 PMID: 12024106
  74. Role of endothelium in the maintenance of low pulmonary vascular tone in normal children.
    Circulation. 1994 May;89(5):2041-4 PMID: 8181127
  75. Survival with first-line bosentan in patients with primary pulmonary hypertension.
    Eur Respir J. 2005 Feb;25(2):244-9 PMID: 15684287
  76. Updated clinical classification of pulmonary hypertension.
    J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-S54 PMID: 19555858
  77. Hypoxia increases AP-1 binding activity by enhancing capacitative Ca2+ entry in human pulmonary artery endothelial cells.
    Am J Physiol Lung Cell Mol Physiol. 2003 Dec;285(6):L1233-45 PMID: 12909593
  78. Primary pulmonary hypertension between inflammation and cancer.
    Chest. 1998 Sep;114(3 Suppl):225S-230S PMID: 9741573
  79. Association of the metabolic syndrome with pulmonary venous hypertension.
    Chest. 2009 Jul;136(1):31-36 PMID: 19188551
  80. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease.
    J Clin Invest. 2000 Jan;105(1):21-34 PMID: 10619858
  81. Attenuated K+ channel gene transcription in primary pulmonary hypertension.
    Lancet. 1998 Mar 7;351(9104):726-7 PMID: 9504523
  82. AMPK and metabolic adaptation by the heart to pressure overload.
    Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H140-8 PMID: 16920812
  83. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.
    Nat Genet. 2000 Sep;26(1):81-4 PMID: 10973254
  84. Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase.
    J Biol Chem. 1998 Aug 7;273(32):20156-61 PMID: 9685360
  85. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis.
    Circ Res. 2001 Mar 30;88(6):555-62 PMID: 11282888
  86. Ventricular pre-excitation and cardiac hypertrophy mimicking hypertrophic cardiomyopathy in a Turkish family with a novel PRKAG2 mutation.
    Eur J Heart Fail. 2006 Nov;8(7):712-5 PMID: 16716659
  87. Increased plasma serotonin in primary pulmonary hypertension.
    Am J Med. 1995 Sep;99(3):249-54 PMID: 7653484
  88. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension.
    FASEB J. 2005 Jul;19(9):1175-7 PMID: 15827267
  89. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Lancet. 2001 Oct 6;358(9288):1119-23 PMID: 11597664
  90. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial.
    J Am Coll Cardiol. 2007 Apr 10;49(14):1566-71 PMID: 17418297
  91. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells.
    Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L668-78 PMID: 12754186
  92. Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension.
    Am J Pathol. 2008 Mar;172(3):615-27 PMID: 18258847
  93. AMP-activated protein kinase: a key stress signaling pathway in the heart.
    Trends Cardiovasc Med. 2005 Apr;15(3):110-8 PMID: 16039971
  94. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
    Am J Respir Crit Care Med. 2005 Jun 1;171(11):1292-7 PMID: 15750042
  95. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.
    Am J Physiol Lung Cell Mol Physiol. 2007 Apr;292(4):L872-8 PMID: 17142350
  96. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.
    Am J Hum Genet. 2000 Sep;67(3):737-44 PMID: 10903931
  97. Disruption of methylarginine metabolism impairs vascular homeostasis.
    Nat Med. 2007 Feb;13(2):198-203 PMID: 17273169
  98. Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells.
    J Biol Chem. 2001 Dec 14;276(50):47650-7 PMID: 11598137
  99. Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion.
    Eur Respir J. 2008 Jan;31(1):135-9 PMID: 18166594
  100. Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.
    Circulation. 2007 Aug 21;116(8):936-43 PMID: 17679618
  101. Primary pulmonary hypertension: natural history and the importance of thrombosis.
    Circulation. 1984 Oct;70(4):580-7 PMID: 6148159
  102. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
    Eur Respir J. 2008 Oct;32(4):881-91 PMID: 18550612
  103. Imatinib for the treatment of pulmonary arterial hypertension.
    N Engl J Med. 2005 Sep 29;353(13):1412-3 PMID: 16192491
  104. Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension.
    Cardiovasc Res. 1996 Jan;31(1):55-62 PMID: 8849589
  105. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension.
    Circulation. 2006 Jun 6;113(22):2630-41 PMID: 16735674
  106. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer.
    Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H570-8 PMID: 18083891
  107. Reversal of experimental pulmonary hypertension by PDGF inhibition.
    J Clin Invest. 2005 Oct;115(10):2811-21 PMID: 16200212
  108. The selective pulmonary vasodilatory effect of inhaled DETA/NO, a novel nitric oxide donor, in ARDS-a pilot human trial.
    J Crit Care. 2004 Mar;19(1):48-53 PMID: 15101006
  109. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure.
    Circulation. 2006 Oct 24;114(17):1883-91 PMID: 17060398
  110. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.
    J Clin Invest. 2008 May;118(5):1846-57 PMID: 18382765
  111. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels.
    Circulation. 2002 Jan 15;105(2):244-50 PMID: 11790708
  112. Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension.
    Am J Respir Crit Care Med. 2006 Apr 1;173(7):798-802 PMID: 16339917
  113. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.
    Circulation. 2007 May 1;115(17):2331-9 PMID: 17438150
  114. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol.
    Am J Respir Crit Care Med. 2003 Feb 15;167(4):580-6 PMID: 12446266
  115. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice.
    Circulation. 2008 Jun 3;117(22):2928-37 PMID: 18506000
  116. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate.
    Mol Ther. 2002 Jul;6(1):119-26 PMID: 12095312
  117. Elastase and the pathobiology of unexplained pulmonary hypertension.
    Chest. 1998 Sep;114(3 Suppl):213S-224S PMID: 9741572
  118. Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension.
    J Heart Lung Transplant. 2008 Dec;27(12):1326-32 PMID: 19059113
  119. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension.
    Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1182-92 PMID: 17277049
  120. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.
    Circulation. 1987 Jul;76(1):135-41 PMID: 2954725
  121. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
    Circ Res. 2007 Mar 30;100(6):923-9 PMID: 17332430
  122. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline.
    Am J Pathol. 2009 Feb;174(2):380-9 PMID: 19116361
  123. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease.
    Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):413-20 PMID: 14656731
  124. Dynamic changes of gene expression in hypoxia-induced right ventricular hypertrophy.
    Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1185-92 PMID: 14630626
  125. Chronic administration of adrenomedullin attenuates hypoxic pulmonary vascular structural remodeling and inhibits proadrenomedullin N-terminal 20-peptide production in rats.
    Peptides. 2007 Apr;28(4):910-9 PMID: 17267073
  126. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis.
    Circ Res. 2004 Oct 15;95(8):830-40 PMID: 15375007
  127. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.
    J Heart Lung Transplant. 1996 Jan;15(1 Pt 1):100-5 PMID: 8820089
  128. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.
    Ann Intern Med. 2002 Apr 2;136(7):515-22 PMID: 11926786
  129. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells.
    Am J Physiol Lung Cell Mol Physiol. 2003 Sep;285(3):L740-54 PMID: 12740218
  130. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension.
    Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13861-6 PMID: 15358862
  131. Inflammation in pulmonary arterial hypertension.
    Eur Respir J. 2003 Aug;22(2):358-63 PMID: 12952274
  132. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension.
    Circulation. 1998 Oct 6;98(14):1400-6 PMID: 9760294
  133. Effects of continuous infusion of atrial natriuretic peptide on the pulmonary hypertension induced by chronic hypoxia in rats.
    Clin Sci (Lond). 1991 Sep;81(3):379-85 PMID: 1655340
  134. Inhibition of elastolysis by SC-37698 reduces development and progression of monocrotaline pulmonary hypertension.
    Am J Physiol. 1991 Oct;261(4 Pt 2):H1255-67 PMID: 1928407
  135. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter.
    FASEB J. 2009 Dec;23(12):4135-47 PMID: 19679640
  136. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension.
    Circulation. 2005 Apr 26;111(16):2126-33 PMID: 15824200
  137. Changes in functional and histological distributions of nitric oxide synthase caused by chronic hypoxia in rat small pulmonary arteries.
    Br J Pharmacol. 2003 Jul;139(5):899-910 PMID: 12839863
  138. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling.
    Circulation. 2006 Jan 17;113(2):286-95 PMID: 16391154
  139. Dexfenfluramine protects against pulmonary hypertension in rats.
    J Appl Physiol (1985). 2002 Nov;93(5):1770-8 PMID: 12381765
  140. Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter.
    Am J Respir Crit Care Med. 2004 Aug 1;170(3):252-9 PMID: 15087293
  141. Underlying aetiology of pulmonary hypertension in 191 patients: a single centre experience.
    Respirology. 2008 Nov;13(6):825-31 PMID: 18811881
  142. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques.
    Am J Respir Crit Care Med. 2006 Aug 15;174(4):437-45 PMID: 16728715
  143. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway.
    Circ Res. 2009 May 22;104(10):1184-91 PMID: 19390056
  144. Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells.
    Circulation. 2003 Aug 19;108(7):889-95 PMID: 12835224
  145. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension.
    Circ Res. 2008 May 23;102(10):1212-21 PMID: 18436795
  146. Polyamines and the development of monocrotaline-induced pulmonary hypertension.
    Am J Physiol. 1984 Oct;247(4 Pt 2):H682-5 PMID: 6437245
  147. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease.
    Circ Res. 2005 Mar 4;96(4):442-50 PMID: 15692087
  148. Right coronary artery flow impairment in patients with pulmonary hypertension.
    Eur Heart J. 2008 Jan;29(1):120-7 PMID: 18065750
  149. Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension.
    Respiration. 2008;75(3):272-80 PMID: 18025812
  150. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
    J Am Coll Cardiol. 2006 May 16;47(10):2049-56 PMID: 16697324
  151. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?
    Ann Intern Med. 1991 Mar 15;114(6):464-9 PMID: 1994793
  152. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.
    J Clin Invest. 2005 Jun;115(6):1479-91 PMID: 15931388
  153. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
    J Pharmacol Exp Ther. 2000 Feb;292(2):512-20 PMID: 10640287
  154. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.
    Ann Intern Med. 1990 Apr 1;112(7):485-91 PMID: 2107780
  155. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.
    N Engl J Med. 1992 Jul 9;327(2):76-81 PMID: 1603139
  156. NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin up-regulation.
    J Biol Chem. 2007 May 18;282(20):15081-9 PMID: 17403661
  157. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.
    N Engl J Med. 2009 Nov 5;361(19):1864-71 PMID: 19890129
  158. Endothelin-1, but not Ang II, activates MAP kinases through c-Src independent Ras-Raf dependent pathways in vascular smooth muscle cells.
    Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):1960-7 PMID: 17569879
  159. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells.
    FASEB J. 2005 Jul;19(9):1178-80 PMID: 15897232
  160. Alterations in a redox oxygen sensing mechanism in chronic hypoxia.
    J Appl Physiol (1985). 2001 Jun;90(6):2249-56 PMID: 11356790
  161. Inhaled NO as a therapeutic agent.
    Cardiovasc Res. 2007 Jul 15;75(2):339-48 PMID: 17544387
  162. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension.
    Nat Med. 2002 Oct;8(10):1129-35 PMID: 12244304
  163. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension.
    Circulation. 2008 Jun 10;117(23):3020-30 PMID: 18519847
  164. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.
    J Med Genet. 2000 Oct;37(10):741-5 PMID: 11015450
  165. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia.
    Cell Metab. 2006 Mar;3(3):177-85 PMID: 16517405
  166. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat.
    Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):793-7 PMID: 1554204
  167. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Ann Intern Med. 2008 Oct 21;149(8):521-30 PMID: 18936500
  168. Pulmonary vascular disease in the developing world.
    Circulation. 2008 Oct 21;118(17):1758-66 PMID: 18936338
  169. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.
    Endocr Rev. 2006 Feb;27(1):47-72 PMID: 16291870
  170. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension.
    Am J Physiol Cell Physiol. 2007 May;292(5):C1837-53 PMID: 17267549
  171. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene.
    Circ Res. 1997 Jul;81(1):34-41 PMID: 9201025
  172. Developmental regulation of GTP-CH1 in the porcine lung and its relationship to pulmonary vascular relaxation.
    Pediatr Res. 2006 Jun;59(6):767-72 PMID: 16641207
  173. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.
    J Clin Invest. 2001 Oct;108(8):1141-50 PMID: 11602621
  174. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms.
    Prog Nucleic Acid Res Mol Biol. 2001;70:33-75 PMID: 11642366
  175. AMP-activated protein kinase and the regulation of Ca2+ signalling in O2-sensing cells.
    J Physiol. 2006 Jul 1;574(Pt 1):113-23 PMID: 16709639
  176. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension.
    Am J Respir Crit Care Med. 1998 Oct;158(4):1061-7 PMID: 9769261
  177. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension.
    Microvasc Res. 2004 Sep;68(2):75-103 PMID: 15313118
  178. Sildenafil citrate therapy for pulmonary arterial hypertension.
    N Engl J Med. 2005 Nov 17;353(20):2148-57 PMID: 16291984
  179. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension.
    Circulation. 2004 Jan 27;109(3):351-6 PMID: 14718403
  180. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.
    J Clin Invest. 2003 May;111(9):1339-46 PMID: 12727925
  181. Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts.
    Br J Pharmacol. 2008 Oct;155(4):606-16 PMID: 18695640
  182. Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats.
    Am J Physiol Heart Circ Physiol. 2003 Nov;285(5):H2125-31 PMID: 14561683
  183. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
    Am J Respir Crit Care Med. 2008 Oct 15;178(8):861-9 PMID: 18689467
  184. BMP signaling controls PASMC KV channel expression in vitro and in vivo.
    Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L841-8 PMID: 16339782
  185. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted.
    Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11418-23 PMID: 17596340
  186. Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study.
    Pediatr Transplant. 2008 Sep;12(6):650-5 PMID: 18466198
  187. Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue.
    Hum Mol Genet. 2008 Oct 15;17(20):3180-90 PMID: 18647753
  188. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.
    Am J Respir Crit Care Med. 2002 Nov 15;166(10):1403-8 PMID: 12406854
  189. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice.
    Circ Res. 2006 Mar 31;98(6):818-27 PMID: 16497988
  190. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.
    Nat Rev Drug Discov. 2006 Sep;5(9):755-68 PMID: 16955067
  191. c-Jun decreases voltage-gated K(+) channel activity in pulmonary artery smooth muscle cells.
    Circulation. 2001 Sep 25;104(13):1557-63 PMID: 11571252
  192. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension.
    Circulation. 2002 Jan 29;105(4):516-21 PMID: 11815437
  193. Acute oxygen-sensing mechanisms.
    N Engl J Med. 2005 Nov 10;353(19):2042-55 PMID: 16282179
  194. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension.
    Hypertension. 2007 Jan;49(1):232-6 PMID: 17130306
  195. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.
    N Engl J Med. 1996 Aug 29;335(9):609-16 PMID: 8692238
  196. Genetic association of the serotonin transporter in pulmonary arterial hypertension.
    Am J Respir Crit Care Med. 2006 Apr 1;173(7):793-7 PMID: 16399993
Article Info
Journal
Circulation
Abbr.
Circulation
ISSN
1524-4539
DOI
10.1161/CIRCULATIONAHA.108.847707
Email
sarcher@medicine.bsd.uchicago.edu
Published
2010-05-11
Pages
2045-66
Language
English
Region
United States
NLM ID
0147763
PMCID
PMC2869481
Subset
IM
Grants
NHLBI NIH HHS · 1RC1HL099462-01 · United States
British Heart Foundation · United Kingdom
NHLBI NIH HHS · RC1 HL099462-01 · United States
NHLBI NIH HHS · RC1 HL099462 · United States
NHLBI NIH HHS · R01 HL071115 · United States
NHLBI NIH HHS · R01 HL071115-06 · United States
NHLBI NIH HHS · R01 HL 65322 · United States
NHLBI NIH HHS · R01 HL113003 · United States
NHLBI NIH HHS · R01 HL065322 · United States
Medical Research Council · United Kingdom
NHLBI NIH HHS · R01-HL071115 · United States
External Links
PubMed source DOI: 10.1161/CIRCULATIONAHA.108.847707 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2